GLSI vs. CGEM, LENZ, PHAR, ABUS, IMNM, EOLS, AUTL, ERAS, ORIC, and VECT
Should you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include Cullinan Therapeutics (CGEM), LENZ Therapeutics (LENZ), Pharming Group (PHAR), Arbutus Biopharma (ABUS), Immunome (IMNM), Evolus (EOLS), Autolus Therapeutics (AUTL), Erasca (ERAS), ORIC Pharmaceuticals (ORIC), and VectivBio (VECT). These companies are all part of the "pharmaceutical products" industry.
Greenwich LifeSciences vs.
Cullinan Therapeutics (NASDAQ:CGEM) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, community ranking, risk, institutional ownership, earnings, analyst recommendations and media sentiment.
In the previous week, Cullinan Therapeutics and Cullinan Therapeutics both had 3 articles in the media. Greenwich LifeSciences' average media sentiment score of 0.80 beat Cullinan Therapeutics' score of 0.49 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.
86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 6.1% of Cullinan Therapeutics shares are owned by company insiders. Comparatively, 51.7% of Greenwich LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Cullinan Therapeutics' return on equity of -26.54% beat Greenwich LifeSciences' return on equity.
Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cullinan Therapeutics currently has a consensus target price of $31.67, suggesting a potential upside of 208.64%. Greenwich LifeSciences has a consensus target price of $38.00, suggesting a potential upside of 195.26%. Given Cullinan Therapeutics' higher possible upside, equities research analysts clearly believe Cullinan Therapeutics is more favorable than Greenwich LifeSciences.
Cullinan Therapeutics has a beta of -0.14, indicating that its share price is 114% less volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500.
Cullinan Therapeutics received 35 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 82.35% of users gave Cullinan Therapeutics an outperform vote while only 41.18% of users gave Greenwich LifeSciences an outperform vote.
Summary
Cullinan Therapeutics beats Greenwich LifeSciences on 8 of the 13 factors compared between the two stocks.
Get Greenwich LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Greenwich LifeSciences Competitors List
Related Companies and Tools
This page (NASDAQ:GLSI) was last updated on 1/21/2025 by MarketBeat.com Staff
